N-3-吡啶基甘氨酸 | 408509-71-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-3-吡啶基甘氨酸
• 中文别名: 2-(吡啶-3-基氨基)乙酸
• 英文名称: N-pyridin-3-yl-glycine
• 英文别名: N-[3]pyridyl-glycine；N-[3]Pyridyl-glycin；N-(β-Pyridyl)-glycin；N-(3-pyridyl)-glycin；2-(Pyridin-3-ylamino)acetic acid
• CAS: 408509-71-7
• 化学式: C₇H₈N₂O₂
• mdl: MFCD08669829
• 分子量: 152.153
• InChiKey: SNOOZPRBQQFWKS-UHFFFAOYSA-N

物化性质

• 熔点：
  237-238 °C (decomp)
• 沸点：
  402.8±25.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于室温、干燥密封环境中。

反应信息

• 作为反应物：
  描述：

  N-3-吡啶基甘氨酸 、 正辛醛 、 足球烯 以 various solvent(s) 为溶剂， 反应 8.0h， 以20%的产率得到
  参考文献：
  名称：

  通过手性C60结合的组氨酸在氢键驱动的锌卟啉折叠剂中的螺旋诱导作用。

  摘要：

  DOI：

  10.1002/anie.200502465
• 作为产物：
  描述：

  bis-[3]pyridylamino-acetic acid ethyl ester 在 盐酸 、 palladium on activated charcoal 作用下， 生成 N-3-吡啶基甘氨酸
  参考文献：
  名称：

  The Preparation of Substituted Hydrazines. II.¹ 3-Pyridylhydrazine via the Phototropic N-(3-Pyridyl)-sydnone²

  摘要：

  DOI：

  10.1021/ja01629a052

文献信息

• [EN] PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA<br/>[FR] DERIVES DE PYRROLYDIN-2-ONE UTILISES COMME INHIBITEURS DE LA THROMBINE ET DU FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2004052851A1

  公开（公告）日：2004-06-24

  The invention relates to compounds of formula (I), wherein : R1 represents hydrogen, C1-4 alkyl, -CH2CO2H, -CH2CO2C1-2alkyl, or -CH2CONR7R8; R2 and R3 independently represent hydrogen, -C1-6alkyl, -C1-3alkylCN, -C1-3alkylCO2H, -C1-4alkylOC1-4alkyl, -C1-4alkylS(O)nC1-4alkyl, -C1-4alkylNR10R11, -C1-3alkylNCO2C1-4alkyl, -C1-3alkylCONR7R8, -C1-3alkylCO2C0-2alkylR9, -C1-3alkylCOC0-2alkylR9, -C1-3alkylCON(R8) C0-2 alkylR9, -C1-3alkylNCO2C0-2alkylR9, -C1-3alkylNCOC0-2alkylR9 or -C0-2alkylR9, with the proviso that one of R2 and R3 is hydrogen and the other is a substituent other than hydrogen; n is an integer between 0 and 2; R4 and R5 together with the nitrogen atom to which they are attached form a morpholino ring; R6 represents a group selected from formula (II) wherein T1 and T2 independently represent CH2, NH, S or O with the proviso that when one of T1 or T2 represents NH, S or O the other represents CH2; M represents CH3, -OH or PO; V represents CH or N; W represents H, CH3, Cl or F; X represents C1, Br, F or -CH3; Y represents CH3 or CF3; Z represents -CH3 or F; R7 and R8 are independently hydrogen, C1-4alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O, N or S; R10 and R11 independently represent C1-4alkyl or together with the N atom towhich they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additionalheteroatom selected from O, N or S; R9 represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: C1-3alkyl or halogen; and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.

  该发明涉及式(I)的化合物，其中：R1代表氢，C1-4烷基，-CH2CO2H，-CH2CO2C1-2烷基，或-CH2CONR7R8；R2和R3独立地代表氢，-C1-6烷基，-C1-3烷基CN，-C1-3烷基CO2H，-C1-4烷基OC1-4烷基，-C1-4烷基S(O)nC1-4烷基，-C1-4烷基NR10R11，-C1-3烷基NCO2C1-4烷基，-C1-3烷基CONR7R8，-C1-3烷基CO2C0-2烷基R9，-C1-3烷基COC0-2烷基R9，-C1-3烷基CON(R8) C0-2烷基R9，-C1-3烷基NCO2C0-2烷基R9，-C1-3烷基NCOC0-2烷基R9或-C0-2烷基R9，但要求R2和R3中的一个为氢，另一个为非氢取代基；n是0到2之间的整数；R4和R5与它们连接的氮原子一起形成吗啡环；R6代表从式(II)中选择的基团，其中T1和T2独立地代表CH2，NH，S或O，但要求当T1或T2代表NH，S或O时，另一个代表CH2；M代表CH3，-OH或PO；V代表CH或N；W代表H，CH3，Cl或F；X代表C1，Br，F或-CH3；Y代表CH3或CF3；Z代表-CH3或F；R7和R8独立地代表氢，C1-4烷基，或者与它们连接的N原子一起形成一个5-或6-成员非芳香杂环，选择性地包含另一个从O，N或S中选择的杂原子；R10和R11独立地代表C1-4烷基，或者与它们连接的N原子一起形成一个5-或6-成员非芳香杂环，选择性地包含另一个从O，N或S中选择的杂原子；R9代表苯基或一个5-或6-成员芳香或非芳香杂环基团，其中至少含有一个从O，N或S中选择的杂原子，每个基团选择性地被0-2个从C1-3烷基或卤素中选择的基团取代；以及其药用可接受的衍生物，其制备方法，含有它们的药物组合物以及在医学中的使用，特别是在改善需要凝血酶抑制剂的临床状况中的使用。
• Highly homogeneous molecular markers for electrophoresis
  申请人：Invitrogen Corporation

  公开号：US20040014082A1

  公开（公告）日：2004-01-22

  The invention relates to marker molecules for identifying physical properties of molecular species separated by the use of electrophoretic systems. The invention further relates to methods for preparing and using marker molecules.

  这项发明涉及用于识别电泳系统分离的分子物种的物理性质的标记分子。该发明还涉及制备和使用标记分子的方法。
• PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF
  申请人：Cai Sui Xiong

  公开号：US20080300191A1

  公开（公告）日：2008-12-04

  Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention

  本申请公开了用于冠状病毒和SARS-CoV，或小RNA病毒的蛋白酶抑制剂，以及利用这些蛋白酶抑制剂预防、减少、改善和治疗由冠状病毒和SARS-CoV，或小RNA病毒引起的疾病或症状的用途。还公开了使用本发明的化合物减少或预防冠状病毒，或小RNA病毒的传播，并预防或减少冠状病毒，或小RNA病毒的复制的方法。
• [EN] BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS<br/>[FR] COMPOSÉS DIACYLHYDRAZINE CONTENANT DU BORE
  申请人：INTREXON CORP

  公开号：WO2016044390A1

  公开（公告）日：2016-03-24

  The present disclosure provides boron-containing diacylhydrazines having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有式（I）的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中A、R4和R5如规范中所述。本公开还提供了含硼二酰肼化合物在蜕皮激素受体基础上的诱导基因表达系统的用途。因此，本公开适用于基因治疗、疾病治疗、大规模蛋白质和抗体生产、基于细胞的筛选分析、功能基因组学、蛋白质组学、代谢组学和调节转基因生物的特征等应用中，其中对基因表达水平的控制是可取的。
• Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa
  申请人：Borthwick David Alan

  公开号：US20060166985A1

  公开（公告）日：2006-07-27

  The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.

  本发明涉及一种新型化合物、其药学上可接受的衍生物、其制备方法、包含它们的制药组合物，以及它们在医学上的使用，特别是在减轻需要凝血酶抑制剂的临床病症中的使用。